Paper894339
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors.
Levin VA and 5 others. J Neurosurg, 1977. Cited by 207 papers, by iCite.
Cite this record
ConductScience Library. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. Papers, record 894339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/894339
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| Antineoplastic Agents | |
| Electroencephalography | |
| Humans | |
| Prognosis | |
| Retrospective Studies | |
| Time Factors | |
| Tomography, X-Ray Computed |
Source PubMed
Cited by72
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 207 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41325560 | STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/41325560 | PubMed |
| 40586994 | RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology. | Jpn J Radiol | 2025 | https://conductscience.org/library/papers/40586994 | PubMed |
| 38968207 | Evaluating soluble Axl as a biomarker for glioblastoma: A pilot study. | PLoS One | 2024 | https://conductscience.org/library/papers/38968207 | PubMed |
| 38170429 | Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas. | Curr Neurol Neurosci Rep | 2024 | https://conductscience.org/library/papers/38170429 | PubMed |
| 37515669 | Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme. | J Neurooncol | 2023 | https://conductscience.org/library/papers/37515669 | PubMed |
| 36858729 | Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/36858729 | PubMed |
| 36386035 | Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study. | EClinicalMedicine | 2023 | https://conductscience.org/library/papers/36386035 | PubMed |
| 35451676 | Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/35451676 | PubMed |
| 33634034 | A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research. | Front Oncol | 2021 | https://conductscience.org/library/papers/33634034 | PubMed |
| 32190946 | Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma. | J Magn Reson Imaging | 2020 | https://conductscience.org/library/papers/32190946 | PubMed |
| 32133275 | Objective response rate assessment in oncology: Current situation and future expectations. | World J Clin Oncol | 2020 | https://conductscience.org/library/papers/32133275 | PubMed |
| 31386050 | Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. | Neurooncol Pract | 2019 | https://conductscience.org/library/papers/31386050 | PubMed |
| 31133966 | Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. | Front Neurol | 2019 | https://conductscience.org/library/papers/31133966 | PubMed |
| 30806082 | Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. | CNS Oncol | 2019 | https://conductscience.org/library/papers/30806082 | PubMed |
| 30411280 | Brain tumour post-treatment imaging and treatment-related complications. | Insights Imaging | 2018 | https://conductscience.org/library/papers/30411280 | PubMed |
| 30258190 | Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. | Sci Rep | 2018 | https://conductscience.org/library/papers/30258190 | PubMed |
| 29897562 | Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29897562 | PubMed |
| 29378419 | Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas. | CNS Oncol | 2018 | https://conductscience.org/library/papers/29378419 | PubMed |
| 29218626 | Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. | Clin Transl Oncol | 2018 | https://conductscience.org/library/papers/29218626 | PubMed |
| 29040703 | Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29040703 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/894339
GET https://conductscience.org/api/papers/v1/894339/cited_by?page=2